

# NEWS 01 2010

## Cerbios appoints Stefano Console as Director Commercial Business Development.

Cerbios-Pharma SA (from now on "Cerbios") announced today that Stefano Console has joined as Director Commercial Business Development.

In this role, Mr. Console will be responsible for managing all aspects of the company's business development for the chemical services sector from the strategic, commercial and relationship management point-of-view.

Prior to joining Cerbios, Mr. Console was Business and Financial Director at Micro-Macinazione SA.

*"We are pleased that Stefano has decided to join the Cerbios team to help us with our strategy to both grow our current business and to strengthen our commercial platform for the services provided in areas such as High Potency Active Ingredients," said Gabriel Haering, CEO. "Stefano brings a wealth of diverse experience in contract manufacturing for the pharmaceutical industry, which will be essential to Cerbios as we continue to expand our unique service platform and address the evolving challenges of this industry."*



After five years spent in Process Development at two different pharmaceutical fine chemical companies, in 1998 he joined the world of third party chemical manufacturing as manager business development.

The broad experience gathered during the past twelve years with different contract manufacturers (including Zambon, Chemi and Flamma) covered strategic roles managing a large number of successful projects for big to small Pharma partners across EU, USA and Japan.

Mr. Console received his degree in chemistry from the University of Milan.

### **About Cerbios-Pharma SA**

Cerbios is a privately held company located in Lugano (Switzerland) specialized in the development and manufacturing of chemical and biological APIs for our partners world-wide.

APIs made by Cerbios cover small molecules (Chemical Division), large molecules and Probiotics (Biological Division).

The Chemical Division has specialized in the past 30 years not only in Reduced Folates (leading position), but also in the manufacturing of High Potency Active Ingredients (HPAIs) with long-term experience in the field of Vitamin D derivatives requiring sophisticated production units with high containment levels.

The Biological Division has specialized since 1976 in the research, development and production of Probiotics as active pharmaceutical ingredients, pharmaceutical finished products and feed additives.

On top of that, in the last 15 years, Cerbios has acquired a vast experience on Recombinant Proteins from mammalian cells (CHO) based on a state-of-the-art platform.

Services for third parties under exclusive manufacturing is offered in the area of HPAIs for the Chemical Division and Recombinant Proteins for the Biological Division.

Full CMC support is provided to our partners in order to provide them with the supply of cGMP clinical batches, registration/validation material and APIs from commercial manufacturing.

Paramount to this is the supply of all documentation required for a successful registration.

For further information, please contact:

### **Cerbios-Pharma SA**

Via Figino 6  
6917 Barbengo/Lugano  
SWITZERLAND

Phone +41 (0) 91 985 63 11

Fax +41 (0) 91 985 63 25

email [info@cerbios.ch](mailto:info@cerbios.ch)

[www.cerbios.ch](http://www.cerbios.ch)

About Cerbios-Pharma SA

Cerbios is a privately held company located in Lugano, Switzerland, that specializes in the development and manufacture of both chemical and biological APIs for its partners world-wide.

Exclusive, third-party manufacturing services are offered by the Chemical Division for HPAs and by the Biological Division for monoclonal antibodies, recombinant proteins and pharma probiotics.

Cerbios provides full CMC support to its world-wide partners, including the supply of cGMP clinical batches, registration/validation material and commercially manufactured APIs. Paramount to this is the ability to supply all of the technical documentation and support necessary for a successful registration. Cerbios' commercial products are marketed worldwide but primarily in Europe, USA, Japan and India